National cohort study of patients with insulin-treated diabetes. v1
Research type
Research Study
Full title
National cohort study of mortality and cancer incidence in patients with insulin-treated diabetes.
IRAS ID
304728
Contact name
Michael Jones
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
55 years, 0 months, 0 days
Research summary
This study has already been running, with ethics and CAG approval, for 30 years. In order to transfer this study to a new Chief Investigator, with no other changes, we have been asked to complete this form, to produce IRAS registration needed for the transfer.
This is a large-scale follow-up study of risks of cancer and mortality in patients with insulin-treated diabetes aged under 50 (largely under 30) at diagnosis who were identified in the UK during 1972-1993. It is to our knowledge the largest study worldwide to provide information on such long-term follow-up of risks of cancer and death in relation to age at onset and duration of diabetes, to inform patients, parents of young patients, and clinicians.
Because modern treatments have led to greatly improved survival of patients with diabetes, the issue of long-term side-effects of the disease has become an important one for advice to patients and (for children) to their parents. It is also important to clinicians deciding about treatment of diseases and the balance of benefit vs. side-effects and complications, and to the Health Service, because of the costs accruing for continued follow-up and care of these patients and the planning required to take account of long-term consequences and to plan strategies, where possible, for their prevention and early detection. There is a great desire on the part of parents of children with this disease to know about their child's prognosis. The condition, is one where there is reason to be concerned about long-term mortality and cancer risks, and a deficiency of large-scale cohort information about this. The study will furnish information to meet these needs, in relation to age of diabetes onset and duration of diabetes, on a larger scale over a longer period than, to our knowledge any other study of young insulin-treated patients.
REC name
London - Central Research Ethics Committee
REC reference
22/LO/0238
Date of REC Opinion
6 Apr 2022
REC opinion
Favourable Opinion